Emerging Targeted Therapeutic Strategies to Overcome Imatinib Resistance of Gastrointestinal Stromal Tumors
Gastrointestinal stromal tumors (GISTs) are the most common malignant mesenchymal neoplasms of the gastrointestinal tract. The gold standard for the diagnosis of GISTs is morphologic analysis with an immunohistochemical evaluation plus genomic profiling to assess the mutational status of lesions. Th...
Main Authors: | Maria Teresa Masucci, Maria Letizia Motti, Michele Minopoli, Gioconda Di Carluccio, Maria Vincenza Carriero |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-03-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/24/7/6026 |
Similar Items
-
Therapeutic Strategies Targeting Urokinase and Its Receptor in Cancer
by: Maria Teresa Masucci, et al.
Published: (2022-01-01) -
Advances in the research of the mechanism of secondary resistance to imatinib in gastrointestinal stromal tumors
by: Xiangchen Hu, et al.
Published: (2022-09-01) -
Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor
by: Chaoyong Shen, et al.
Published: (2014-11-01) -
Heterogeneity of Metabolic Vulnerability in Imatinib-Resistant Gastrointestinal Stromal Tumor
by: Wen-Kuan Huang, et al.
Published: (2020-05-01) -
Surgical intervention of a giant gastric gastrointestinal stromal tumor following neoadjuvant therapy with imatinib
by: Chien-Yang Wang, et al.
Published: (2018-01-01)